Melanotan 2 is sometimes described online as an aphrodisiac or sexual-performance enhancer. These descriptions originate partly from small human studies in which erections and increased sexual desire were reported. However, the evidence is limited, and Melanotan 2 is not an authorised treatment for erectile dysfunction or reduced libido.
This article explains what the published studies found, the difference between sexual desire and a physical erection, and why the results should not be interpreted as proof of a safe or established treatment.
Why Is Melanotan 2 Associated With Sexual Arousal?
Melanotan 2 is a synthetic cyclic peptide related to alpha-melanocyte-stimulating hormone, usually abbreviated to alpha-MSH.
It can interact with several melanocortin receptors. Its effect on skin pigmentation is associated primarily with activity at the MC1 receptor. Its reported sexual effects are thought to involve central melanocortin pathways, particularly receptors including MC3 and MC4.
This proposed mechanism is different from medicines that primarily influence blood flow to the penis. Melanotan 2 appears capable of affecting brain pathways involved in erectile responses and sexual motivation.
However, the human trials did not directly measure receptor activity inside the participants’ brains. The proposed central mechanism is supported by pharmacological and animal research rather than being directly demonstrated in those small human studies.
Is Melanotan 2 Really an Aphrodisiac?
The word “aphrodisiac” is informal and can be misleading because it combines several different experiences:
- Sexual desire or libido
- Subjective arousal
- A physical erection
- Genital sensitivity
- Sexual performance
These outcomes are related, but they are not interchangeable.
A physical erection can occur without increased sexual desire. Equally, increased desire does not guarantee an erection or improved sexual performance.
The Melanotan 2 studies provide evidence that erections occurred in some male participants. One study also recorded increased reports of sexual desire. They did not establish that Melanotan 2 reliably improves every aspect of sexual function.
The First Unexpected Sexual Effects
The first published human study of Melanotan 2 was a Phase I pilot involving three healthy male volunteers.[1]
The study was primarily investigating tolerability and pigmentation. During the experimental period, researchers observed a stretching and yawning response accompanied by spontaneous penile erections.
The erections occurred without planned sexual stimulation and reportedly lasted intermittently for between one and five hours, depending on the participant and experimental dose.
This was an unexpected finding rather than the original purpose of the research. It encouraged further investigation into the relationship between melanocortin signalling and erectile function.
The study involved only three men, so it could not establish how commonly this response occurs or predict how another person would react.
Study in Men With Psychogenic Erectile Dysfunction
A 1998 double-blind, placebo-controlled crossover study investigated Melanotan 2 in ten men with erectile dysfunction that had no identified organic cause.[2]
The participants received Melanotan 2 and placebo during separate study sessions. Penile rigidity was monitored using RigiScan equipment during a six-hour observation period.
Following Melanotan 2:
- Eight of the ten participants developed clinically apparent erections
- Mean tip rigidity above 80 percent lasted approximately 38 minutes
- Mean tip rigidity above 80 percent lasted approximately 3 minutes following placebo
The erections occurred without deliberate erotic stimulation during the monitoring period.
These findings support the conclusion that Melanotan 2 can initiate an erectile response in some men. They do not establish that it provides reliable sexual performance in ordinary circumstances or that it is suitable as a treatment.
Reported Adverse Effects
Nausea, stretching, yawning and reduced appetite were reported more frequently after Melanotan 2 than after placebo.
The researchers considered the compound biologically active, but the study population was extremely small and the observation period was short.
Study in Men With Organic Erectile Dysfunction
A later double-blind, placebo-controlled crossover study involved ten men whose erectile dysfunction was associated with organic risk factors.[3]
Across the study sessions, participants received 19 Melanotan 2 injections and 21 placebo injections. One participant underwent additional placebo sessions, which is why the injection totals exceeded the participant number.
Subjectively reported erections occurred following:
- 12 of 19 Melanotan 2 injections
- 1 of 21 placebo injections
The average duration of tip rigidity above 80 percent was approximately:
- 45.3 minutes following Melanotan 2
- 1.9 minutes following placebo
This study also asked participants about sexual desire. Increased desire was reported after 13 of 19 Melanotan 2 doses, compared with 4 of 21 placebo doses.
This is more direct evidence of a reported effect on sexual motivation than the observation of an erection alone. However, it still came from only ten participants.
Nausea Was a Significant Limitation
Nausea and stretching or yawning were again frequently reported. Severe nausea occurred after four of the 19 Melanotan 2 injections.
The results therefore demonstrated both sexual effects and a meaningful tolerability problem. It would be misleading to describe the reported effects without also explaining the adverse findings.
What Did the Combined 20-Man Analysis Show?
A later publication discussed findings from 20 men with psychogenic or organic erectile dysfunction.[4]
It reported that:
- 17 of the 20 men developed erections following Melanotan 2
- Average tip rigidity above 80 percent lasted approximately 41 minutes
- Increased sexual desire was reported after 68 percent of active doses
- Increased sexual desire was reported after 19 percent of placebo doses
- Nausea and yawning were frequently reported
This publication did not represent a separate trial involving another 20 men. It combined the two previously described groups of ten participants.
The principal controlled evidence therefore remains two small erectile-function studies involving 20 men in total.
Do These Results Prove That MT2 Treats Erectile Dysfunction?
No. The studies demonstrated an erectile response in some participants under controlled experimental conditions, but they did not establish an authorised medical treatment.
Important limitations include:
- Only 20 men participated across the two erectile-function studies
- The observation periods were short
- Long-term effectiveness was not established
- Long-term safety was not established
- The studies did not compare Melanotan 2 with established ED treatments
- The trials did not determine which patients might benefit or be harmed
- The research products cannot automatically be equated with unregulated products sold online
Melanotan 2 is not a licensed treatment for erectile dysfunction. Anyone experiencing persistent erectile difficulties should speak to a qualified healthcare professional because erectile dysfunction can be associated with cardiovascular, hormonal, neurological, psychological or medication-related factors.
What About Sexual Effects in Women?
The principal Melanotan 2 human studies discussed here involved men. They do not provide reliable clinical evidence about sexual desire, arousal or safety in women.
Animal research and later studies involving related melanocortin compounds have examined female sexual response. Those findings should not be presented as though they were direct Melanotan 2 trials in women.
Claims that Melanotan 2 reliably increases female libido are therefore not supported by these human studies.
Melanotan 2 and Bremelanotide Are Not the Same
Bremelanotide, also known during development as PT-141, is related to Melanotan 2 but is a different compound.
Its development was influenced by research into melanocortin signalling and the sexual effects observed with Melanotan 2. However, clinical trials involving bremelanotide provide evidence about bremelanotide, not Melanotan 2.
The approval or clinical use of a related medicine cannot be used to claim that Melanotan 2 has also been approved, clinically validated or shown to have the same safety profile.
What Is the Risk of Priapism?
Priapism is a prolonged erection that does not resolve normally. It can be painful and can cause permanent tissue damage if treatment is delayed.
A published case report described priapism following the use of Melanotan 2.[5] A case report cannot establish how frequently this happens, but it demonstrates that a prolonged erection should not be regarded simply as a desirable sexual effect.
The NHS advises calling 999 or attending A&E for an erection lasting more than three to four hours.[6]
Urgent assessment is particularly important if the erection is painful. Sexual activity or masturbation should not be relied upon to make priapism resolve.
Other Reported Effects
The controlled studies reported several effects alongside erections and sexual desire:
- Nausea
- Stretching and yawning
- Reduced appetite
- Fatigue or somnolence at a higher experimental dose
- Changes in skin pigmentation
Later case reports have described additional medical events following the use of unlicensed Melanotan products. Case reports can identify potential safety signals, but they cannot determine the frequency of an event or prove that Melanotan 2 was the sole cause.
Read our broader guide to the possible effects and side effects of Melanotan 2.
Why Online Experiences Require Caution
Online reports frequently describe increased libido, stronger erections, heightened sensitivity or changes in sexual confidence.
These experiences may be genuine accounts of what an individual noticed, but they remain anecdotal. They cannot establish:
- What substance was actually used
- Its strength, purity or composition
- Whether another medicine or health condition contributed
- How commonly the reported effect occurs
- Whether another person will experience the same outcome
Anecdotal experience should not be presented as equivalent to a controlled clinical study.
What Laboratory Testing Can Show
Independent laboratory analysis can provide information about the identity, measured content and reported purity of the submitted sample. It cannot establish sexual effects, clinical safety or effectiveness.
Pure MT2 publishes its available independent laboratory analysis. The document reports that the submitted sample was identified as Melanotan II, with measured content of 9.97mg and reported purity of 99%.
Those findings apply only to the sample identified by laboratory order number 100011931. The report does not establish:
- An effect on libido or erectile function
- Clinical safety or effectiveness
- Sterility or suitability for human use
- How any individual will respond
- The composition of a different sample, lot or batch
UK Regulatory Position
Melanotan 2 is not a licensed medicine in the United Kingdom.
The UK Government has previously stated that no Melanotan product holds UK marketing authorisation and that Melanotan products are subject to medicines regulation.[7]
It has not been authorised as a treatment for erectile dysfunction, reduced libido or another sexual-health condition.
So, Does Melanotan 2 Affect Sexual Arousal?
Small human studies provide evidence that Melanotan 2 can initiate erections in some men and may affect reported sexual desire.
However, erection, desire, arousal and sexual performance are different outcomes. The research does not establish that every user will experience a positive sexual effect or that Melanotan 2 is a safe and effective treatment.
The evidence remains limited to small, short-term studies. Nausea, stretching, yawning and reduced appetite were common, and prolonged erection is a potentially serious risk.
The most accurate conclusion is that sexual effects have been demonstrated in limited human research, while the wider safety, effectiveness and predictability of those effects remain inadequately established.
For a study-by-study overview, read our guide to the human research involving Melanotan 2.
Important Information
This article is provided for general educational purposes. It does not provide medical advice or recommend Melanotan 2 as a treatment for erectile dysfunction, reduced libido or another condition.
Anyone with persistent erectile difficulties should seek advice from a qualified healthcare professional. Call 999 or attend A&E for an erection lasting more than three to four hours.
Sources and Further Reading
- Dorr RT, et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996.
- Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo-controlled crossover study. Journal of Urology. 1998.
- Wessells H, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000.
- Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research. 2000.
- Dreyer BA, et al. Melanotan-induced priapism: a hard-earned tan. BMJ Case Reports. 2019.
- NHS. Priapism (painful erections). Reviewed 5 December 2023.
- UK Parliament. Melanotan and UK regulatory controls. Answered 16 June 2014.
Last evidence review: 18 September 2026.